Investigating Mechanisms and Causes Related to Angiogenesis: A Review

The increasing resistance of cancers to common treatments has caused researchers to make more efforts to discover and identify new anticancer agents. Excessive use of chemical drugs increases the resistance of cancer cells, and as a result, treatment measures fail due to a decrease in the response level of these cells to the drug. Therefore, it is extremely important to study drugs that are more effective and have fewer side effects. Angiogenesis is a new treatment method that has been studied recently due to the high importance of this treatment method and the efficiency of this method in the treatment of some diseases, including all types of tumors. There are many hopes for the use of this method. It has created an effective method. Among the most important potential advantages of this method in cancer treatment, we can mention the absence of cell resistance problems, easy access to intravascular targets, as well as the wide scope of using this type of strategy to treat many types of diseases related to angiogenesis. Therefore, the use of different angiogenesis models and the development of these models can be very important for the treatment of all types of cancer and other diseases. In this review article, various dimensions of the angiogenesis process and the mechanisms and factors related to it, as well as the studies surrounding them, have been discussed.

1. Breier G. Angiogenesis in embryonic development--A review. Placenta. 2000;21 Suppl A:S11-5. 
2. Coppola R, Santo B, Ramella S, Panasiti V. Novel skin toxicity of epidermal growth factor receptor inhibitors: A case of intertrigo-like eruption in a patient with metastatic colorectal cancer treated with cetuximab. Clin Cancer Investig J. 2021;10(2):91-2.
3. Mahmood H, Shahid AM, Usama M, Nadeem E, Zafar N, Bashir R. Relation between periodontitis and systemic health among young dental practitioners in twin cities of Pakistan. Ann Dent Spec. 2022;10(3):7-11.
4. Turkistani S, Alotaibi N, Alanazi MM, Alsanie SA, Hussain BS, Hasan S. Efficacy of glass fiber composite restoration: A systematic review. Arch Pharm Pract. 2022;13(3):123.
5. Mostafaei A, Mohammadi Motlagh HR, Mansouri K. Angiogenesis and the models to study Angiogenesis. Cell J. 2010;11(4):374-81.
6. Fox SB, Gasparini G, Harris AL. Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2001;2(5):278-89. 
7. Nebotova LV, Gasanov EA, Makhsubova SH, Abdullayeva ZA, Shabaev SM, Kadiev IA. Methods of treatment of hemangiomas. Clin Cancer Investig J. 2023;12(2):33-8.
8. Özatik Ş, Saygılı S, Sülün T, Alan CB. Semi-digital workflow of removable partial denture fabrication for scleroderma-induced microstomia patients: Two clinical reports. Ann Dent Spec. 2022;10(3):1-6.
9. Bielenberg DR, D'Amore PA. Judah Folkman's contribution to the inhibition of angiogenesis. Lymphat Res Biol. 2008;6(3-4):203-7. 
10. Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med. 1975;141(2):427-39. 
11. Bakhuraysah MM. Immunity and therapeutic approaches against coronavirus disease 2019. Arch Pharm Pract. 2022;13(3):105-11.
12. Dogan I, Khanmammadov N, Ahmed MA, Yıldız A, Saip P, Aydiner A, et al. Outcomes and prognostic factors in patients with EGFR mutant metastatic non-small cell lung cancer who treated with Erlotinib. Clin Cancer Investig J. 2022;11(4):5-9.
13. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-8.
14. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84(24):1875-87.
15. Poornachitra P, Maheswari U. Prevalence of non-specific chief complaints in patients with oral submucous fibrosis. Ann Dent Spec. 2022;10(3):59-63.
16. Elsawy A, Alkhalaf R, Binnjefan S, Alkhalaf K, Alhumaidan S, Haridy R. Temporomandibular disorders: A cross sectional study into the knowledge and awareness among Saudi Arabian population. Arch Pharm Pract. 2022;13(3):116-21.
17. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-85.
18. Talu H, Taşindi E, Ciftci F, Yildiz TF. Excimer laser phototherapeutic keratectomy for recurrent pterygium. J Cataract Refract Surg. 1998;24(10):1326-32. 
19. Singh G, Goel N, Singh A, Gera R. Study of factors affecting the time to diagnosis and treatment in pediatric acute leukemia patients- a study from India. Clin Cancer Investig J. 2022;11(3):35-40.
20. Robson MC, Payne WG, Garner WL, Biundo J, Giacalone VF, Cooper DM, et al. Integrating the results of phase IV (postmarketing) clinical trial with four previous trials reinforces the position that Regranex (Becaplermin) Gel 0.01% is an effective adjunct to the treatment of diabetic foot ulcers. J Appl Res 2005;5:35-45.
21. Shimizu K, Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull. 2004;27(5):599-605.
22. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423-36. 
23. Gupta K, Zhang J. Angiogenesis: A curse or cure? Postgrad Med J. 2005;81(954):236-42. 
24. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91(10):3527-61. 
25. Verstraete M. Endothelial cell-mediated coagulation, anticoagulation and fibrinolysis. In: The Endothelial Cell in Health and Disease, eds Vane JR, Born GVR, Welzel D (Schattauer, Stuttgart, New York), 1995; pp 147-64.
26. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, et al. Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent. Biochem Biophys Res Commun. 1991;174(3):1070-6. 
27. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci U S A. 1995;92(17):7799-803. 
28. Lee JH, Chun T, Park SY, Rho SB. Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs. Biochim Biophys Acta. 2008;1783(9):1654-62. 
29. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79(2):315-28.
30. Streck CJ, Ng CY, Zhang Y, Zhou J, Nathwani AC, Davidoff AM. Interferon-mediated anti-angiogenic therapy for neuroblastoma. Cancer Lett. 2005;228(1-2):163-70. 
31. Gruner S, Liebenthal C, Heusser C, Brinkmann V, Zwirner A, Reinicke C, et al. The influence of interferon-gamma and interleukin-4 on IgE production in B lymphocytes of patients with atopic dermatitis. A possible criterion for selection of patients for interferon therapy. Acta Derm Venereol. 1991;71(6):484-7. 
32. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841-4.
33. Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 1993;69(5):508-17.
34. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353-64. 
35. Shakiba Y, Mansouri K, Arshadi D, Rezaei N. Corneal neovascularization: Molecular events and therapeutic options. Recent Pat Inflamm Allergy Drug Discov. 2009;3(3):221-31. 
36. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843-5. 
37. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87(7):1161-9. 
38. Kohn S, Nagy JA, Dvorak HF, Dvorak AM. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest. 1992;67(5):596-607.
39. Kevil CG, Payne DK, Mire E, Alexander JS. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem. 1998;273(24):15099-103. 
40. Vila V, Martínez-Sales V, Almenar L, Lázaro IS, Villa P, Reganon E. Inflammation, endothelial dysfunction and angiogenesis markers in chronic heart failure patients. Int J Cardiol. 2008;130(2):276-7.
41. Kiefer FN, Munk VC, Humar R, Dieterle T, Landmann L, Battegay EJ. A versatile in vitro assay for investigating angiogenesis of the heart. Exp Cell Res. 2004;300(2):272-82. 
42. Grass TM, Lurie DI, Coffin JD. Transitional angiogenesis and vascular remodeling during coronary angiogenesis in response to myocardial infarction. Acta Histochem. 2006;108(4):293-302.
43. Renault MA, Losordo DW. Therapeutic myocardial angiogenesis. Microvasc Res. 2007;74(2-3):159-71. 
44. Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms in heart failure: Focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol. 2006;48(9):56-66.
45. Epstein SE, Stabile E, Kinnaird T, Lee CW, Clavijo L, Burnett MS. Janus phenomenon: The interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation. 2004;109(23):2826-31.
46. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol. 2001;19(3):851-6. 
47. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10(6):415-33. 
48. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43 Suppl:S42-51. 
49. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19(56):6642-50.
50. Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 1996;56(22):5279-84.